SCHEMBL5382809

SCHEMBL5382809

Cn1nc(Cc2ccc(F)cc2)cc1-c1cccc(I)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FYN P06241 5/20 0.43
HDAC6 Q9UBN7 2/20 0.41
GPR52 Q9Y2T5 1/20 0.40
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
CYP17A1 P05093 1/20 0.36
CYP3A4 P08684 1/20 0.36
MET P08581 1/20 0.34
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HTR2C P28335 2/20 0.33
BCHE P06276 1/20 0.32
HDAC3 O15379 1/20 0.32
HDAC4 P56524 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC7 Q8WUI4 1/20 0.32
HDAC2 Q92769 1/20 0.32
HDAC10 Q969S8 1/20 0.32
HDAC11 Q96DB2 1/20 0.32
HDAC8 Q9BY41 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5382808 0.82 GABRG2 (0.43) FYNHDAC6GPR52CYP11B1CYP11B2
SCHEMBL5406662 0.81 GPR52 (0.46) FYNHDAC6GPR52MAPTBCHE
SCHEMBL14015420 0.68 HDAC6 (0.50) HDAC6GPR52CYP3A4HDAC3HDAC4
SCHEMBL21807369 0.67 CSNK1D (0.46) FYNHDAC6GPR52HDAC3HDAC4
SCHEMBL5417813 0.66 HDAC6 (0.52) HDAC6GPR52HDAC3HDAC4HDAC1
SCHEMBL28708641 0.65 KEAP1 (0.38) LMNA
SCHEMBL1603814 0.65 FYN (0.54) FYNHDAC6HDAC3HDAC4HDAC1
SCHEMBL18759003 0.65 AGXT (0.47) CYP11B1CYP11B2CYP17A1CYP3A4HTR2C
SCHEMBL5763782 0.64 PLAT (0.44) METHTR2C
SCHEMBL28718890 0.64 PIK3CD (0.43) CYP3A4LMNAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7271191-B2 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease MERCK SHARP & DOHME LTD. (GB) 2007-09-18 US disclosed
US-7271191-B2 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease MERCK SHARP & DOHME LTD. (GB) 2007-09-18 US disclosed
US-7271191-B2 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of Alzheimer's disease MERCK SHARP & DOHME LTD. (GB) 2007-09-18 US disclosed
US-20060264474-A1 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease MERCK SHARP & DOHME LTD. (GB) 2006-11-23 US disclosed
WO-2004089911-A1 PYRAZOLE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS USEFUL IN THE TREATMENT OF ALZHEIMER’S DISEASE MERCK SHARP & DOHME LIMITED (GB) 2004-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264474-A1 Pyrazole derivatives as gamma-secretase inhibitors useful in the treatment of alzheimer's disease BACE1, BACE2, PSEN1 FYN 1228/4885HDAC6 1518/4885GPR52 2413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.